Intrinsic value of Stericycle - SRCL

Previous Close

$85.56

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$85.56

 
Intrinsic value

$63.10

 
Up/down potential

-26%

 
Rating

sell

 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of SRCL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 7.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  19.29
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  3,562
  3,633
  3,717
  3,812
  3,920
  4,038
  4,169
  4,311
  4,464
  4,630
  4,808
  4,998
  5,201
  5,417
  5,646
  5,890
  6,148
  6,421
  6,710
  7,015
  7,338
  7,678
  8,036
  8,414
  8,813
  9,232
  9,674
  10,139
  10,628
  11,143
  11,684
Variable operating expenses, $m
 
  3,034
  3,095
  3,166
  3,245
  3,332
  3,428
  3,533
  3,646
  3,768
  3,898
  3,679
  3,829
  3,988
  4,157
  4,336
  4,526
  4,727
  4,940
  5,164
  5,402
  5,652
  5,916
  6,195
  6,488
  6,797
  7,122
  7,464
  7,824
  8,203
  8,602
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,129
  3,034
  3,095
  3,166
  3,245
  3,332
  3,428
  3,533
  3,646
  3,768
  3,898
  3,679
  3,829
  3,988
  4,157
  4,336
  4,526
  4,727
  4,940
  5,164
  5,402
  5,652
  5,916
  6,195
  6,488
  6,797
  7,122
  7,464
  7,824
  8,203
  8,602
Operating income, $m
  434
  599
  621
  647
  675
  706
  741
  778
  819
  862
  909
  1,318
  1,372
  1,429
  1,490
  1,554
  1,622
  1,694
  1,770
  1,851
  1,936
  2,025
  2,120
  2,220
  2,325
  2,436
  2,552
  2,675
  2,804
  2,940
  3,082
EBITDA, $m
  686
  1,064
  1,088
  1,116
  1,147
  1,182
  1,220
  1,262
  1,307
  1,355
  1,408
  1,463
  1,523
  1,586
  1,653
  1,724
  1,800
  1,880
  1,964
  2,054
  2,148
  2,248
  2,353
  2,463
  2,580
  2,703
  2,832
  2,968
  3,112
  3,262
  3,421
Interest expense (income), $m
  89
  102
  104
  108
  112
  116
  121
  126
  132
  138
  145
  152
  160
  168
  177
  186
  196
  206
  217
  229
  241
  254
  268
  283
  298
  314
  331
  349
  368
  388
  409
Earnings before tax, $m
  328
  498
  517
  539
  563
  590
  620
  652
  687
  724
  764
  1,167
  1,212
  1,261
  1,313
  1,368
  1,426
  1,488
  1,553
  1,622
  1,694
  1,771
  1,852
  1,937
  2,027
  2,121
  2,221
  2,326
  2,436
  2,552
  2,674
Tax expense, $m
  120
  134
  140
  146
  152
  159
  167
  176
  185
  196
  206
  315
  327
  340
  354
  369
  385
  402
  419
  438
  457
  478
  500
  523
  547
  573
  600
  628
  658
  689
  722
Net income, $m
  206
  363
  377
  393
  411
  431
  453
  476
  501
  529
  558
  852
  885
  921
  958
  999
  1,041
  1,086
  1,134
  1,184
  1,237
  1,293
  1,352
  1,414
  1,480
  1,549
  1,621
  1,698
  1,778
  1,863
  1,952

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  44
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  6,980
  7,069
  7,231
  7,417
  7,626
  7,857
  8,110
  8,387
  8,686
  9,008
  9,353
  9,723
  10,118
  10,538
  10,985
  11,459
  11,961
  12,492
  13,054
  13,648
  14,275
  14,937
  15,635
  16,370
  17,145
  17,962
  18,821
  19,726
  20,677
  21,679
  22,732
Adjusted assets (=assets-cash), $m
  6,936
  7,069
  7,231
  7,417
  7,626
  7,857
  8,110
  8,387
  8,686
  9,008
  9,353
  9,723
  10,118
  10,538
  10,985
  11,459
  11,961
  12,492
  13,054
  13,648
  14,275
  14,937
  15,635
  16,370
  17,145
  17,962
  18,821
  19,726
  20,677
  21,679
  22,732
Revenue / Adjusted assets
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
Average production assets, $m
  2,548
  2,598
  2,658
  2,726
  2,802
  2,887
  2,981
  3,082
  3,192
  3,310
  3,437
  3,573
  3,718
  3,873
  4,037
  4,211
  4,396
  4,591
  4,798
  5,016
  5,246
  5,490
  5,746
  6,016
  6,301
  6,601
  6,917
  7,249
  7,599
  7,967
  8,354
Working capital, $m
  231
  265
  271
  278
  286
  295
  304
  315
  326
  338
  351
  365
  380
  395
  412
  430
  449
  469
  490
  512
  536
  560
  587
  614
  643
  674
  706
  740
  776
  813
  853
Total debt, $m
  2,950
  2,982
  3,079
  3,189
  3,313
  3,451
  3,602
  3,766
  3,944
  4,136
  4,341
  4,561
  4,796
  5,046
  5,312
  5,594
  5,893
  6,209
  6,543
  6,897
  7,270
  7,664
  8,079
  8,516
  8,978
  9,463
  9,975
  10,513
  11,079
  11,675
  12,302
Total liabilities, $m
  4,174
  4,206
  4,303
  4,413
  4,537
  4,675
  4,826
  4,990
  5,168
  5,360
  5,565
  5,785
  6,020
  6,270
  6,536
  6,818
  7,117
  7,433
  7,767
  8,121
  8,494
  8,888
  9,303
  9,740
  10,202
  10,687
  11,199
  11,737
  12,303
  12,899
  13,526
Total equity, $m
  2,806
  2,863
  2,929
  3,004
  3,088
  3,182
  3,285
  3,397
  3,518
  3,648
  3,788
  3,938
  4,098
  4,268
  4,449
  4,641
  4,844
  5,059
  5,287
  5,528
  5,782
  6,050
  6,332
  6,630
  6,944
  7,274
  7,623
  7,989
  8,374
  8,780
  9,207
Total liabilities and equity, $m
  6,980
  7,069
  7,232
  7,417
  7,625
  7,857
  8,111
  8,387
  8,686
  9,008
  9,353
  9,723
  10,118
  10,538
  10,985
  11,459
  11,961
  12,492
  13,054
  13,649
  14,276
  14,938
  15,635
  16,370
  17,146
  17,961
  18,822
  19,726
  20,677
  21,679
  22,733
Debt-to-equity ratio
  1.051
  1.040
  1.050
  1.060
  1.070
  1.080
  1.100
  1.110
  1.120
  1.130
  1.150
  1.160
  1.170
  1.180
  1.190
  1.210
  1.220
  1.230
  1.240
  1.250
  1.260
  1.270
  1.280
  1.280
  1.290
  1.300
  1.310
  1.320
  1.320
  1.330
  1.340
Adjusted equity ratio
  0.398
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  206
  363
  377
  393
  411
  431
  453
  476
  501
  529
  558
  852
  885
  921
  958
  999
  1,041
  1,086
  1,134
  1,184
  1,237
  1,293
  1,352
  1,414
  1,480
  1,549
  1,621
  1,698
  1,778
  1,863
  1,952
Depreciation, amort., depletion, $m
  252
  464
  467
  469
  473
  476
  480
  484
  488
  493
  498
  145
  151
  157
  163
  170
  178
  186
  194
  203
  212
  222
  233
  244
  255
  267
  280
  293
  308
  323
  338
Funds from operations, $m
  577
  828
  844
  863
  884
  907
  932
  960
  990
  1,022
  1,056
  996
  1,036
  1,077
  1,122
  1,169
  1,219
  1,272
  1,328
  1,387
  1,449
  1,515
  1,584
  1,658
  1,735
  1,816
  1,901
  1,991
  2,086
  2,185
  2,290
Change in working capital, $m
  30
  5
  6
  7
  8
  9
  10
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  22
  24
  25
  26
  28
  29
  31
  32
  34
  36
  38
  40
Cash from operations, $m
  547
  861
  838
  856
  876
  898
  923
  950
  979
  1,010
  1,043
  982
  1,021
  1,062
  1,105
  1,151
  1,200
  1,252
  1,307
  1,365
  1,426
  1,490
  1,558
  1,630
  1,706
  1,785
  1,869
  1,957
  2,050
  2,148
  2,251
Maintenance CAPEX, $m
  0
  -103
  -105
  -108
  -110
  -113
  -117
  -121
  -125
  -129
  -134
  -139
  -145
  -151
  -157
  -163
  -170
  -178
  -186
  -194
  -203
  -212
  -222
  -233
  -244
  -255
  -267
  -280
  -293
  -308
  -323
New CAPEX, $m
  -136
  -50
  -60
  -68
  -77
  -85
  -93
  -102
  -110
  -118
  -127
  -136
  -145
  -154
  -164
  -174
  -185
  -195
  -207
  -218
  -230
  -243
  -256
  -270
  -285
  -300
  -316
  -332
  -350
  -368
  -387
Cash from investing activities, $m
  -196
  -153
  -165
  -176
  -187
  -198
  -210
  -223
  -235
  -247
  -261
  -275
  -290
  -305
  -321
  -337
  -355
  -373
  -393
  -412
  -433
  -455
  -478
  -503
  -529
  -555
  -583
  -612
  -643
  -676
  -710
Free cash flow, $m
  351
  707
  673
  680
  689
  700
  713
  727
  744
  762
  782
  707
  731
  757
  784
  814
  845
  879
  914
  952
  992
  1,035
  1,080
  1,127
  1,177
  1,230
  1,286
  1,345
  1,407
  1,472
  1,541
Issuance/(repayment) of debt, $m
  -281
  76
  97
  111
  124
  138
  151
  164
  178
  192
  206
  220
  235
  250
  266
  282
  299
  316
  334
  353
  373
  394
  415
  438
  461
  486
  511
  538
  566
  596
  627
Issuance/(repurchase) of shares, $m
  -34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -324
  76
  97
  111
  124
  138
  151
  164
  178
  192
  206
  220
  235
  250
  266
  282
  299
  316
  334
  353
  373
  394
  415
  438
  461
  486
  511
  538
  566
  596
  627
Total cash flow (excl. dividends), $m
  28
  783
  770
  791
  813
  837
  864
  892
  922
  954
  988
  927
  966
  1,007
  1,050
  1,096
  1,144
  1,195
  1,249
  1,306
  1,365
  1,428
  1,495
  1,565
  1,638
  1,716
  1,797
  1,883
  1,973
  2,068
  2,168
Retained Cash Flow (-), $m
  -76
  -57
  -66
  -75
  -84
  -94
  -103
  -112
  -121
  -130
  -140
  -150
  -160
  -170
  -181
  -192
  -203
  -215
  -228
  -241
  -254
  -268
  -283
  -298
  -314
  -331
  -348
  -366
  -386
  -406
  -427
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  727
  704
  715
  729
  744
  761
  780
  801
  823
  848
  778
  806
  837
  869
  904
  941
  980
  1,021
  1,065
  1,111
  1,160
  1,212
  1,267
  1,324
  1,385
  1,449
  1,517
  1,588
  1,662
  1,741
Discount rate, %
 
  8.20
  8.61
  9.04
  9.49
  9.97
  10.47
  10.99
  11.54
  12.12
  12.72
  13.36
  14.02
  14.73
  15.46
  16.24
  17.05
  17.90
  18.79
  19.73
  20.72
  21.76
  22.84
  23.99
  25.19
  26.45
  27.77
  29.16
  30.61
  32.15
  33.75
PV of cash for distribution, $m
 
  671
  597
  552
  507
  463
  419
  376
  334
  294
  256
  196
  167
  140
  116
  95
  76
  60
  46
  35
  26
  19
  13
  9
  6
  4
  2
  2
  1
  1
  0
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally. The company collects and processes regulated and specialized waste for disposal services, as well as collects personal and confidential information for secure destruction. It offers regulated solutions for medical waste disposal, pharmaceutical waste disposal, and hazardous waste management; sustainability solutions for expired or unused inventory; and secures information destruction of documents and e-media. The company’s compliance solutions comprise Steri-Safe and clinical services programs for training and consulting; inbound/outbound communications; data reporting; and other regulatory compliance services. It also provides reusable sharps disposal management services, integrated waste stream solutions program, and regulated recall and returns management services for expired or recalled products. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, and long-term care facilities; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was founded in 1989 and is headquartered in Lake Forest, Illinois.

FINANCIAL RATIOS  of  Stericycle (SRCL)

Valuation Ratios
P/E Ratio 35.4
Price to Sales 2
Price to Book 2.6
Price to Tangible Book
Price to Cash Flow 13.3
Price to Free Cash Flow 17.7
Growth Rates
Sales Growth Rate 19.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 18.3%
Cap. Spend. - 3 Yr. Gr. Rate 13.3%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity 102.5%
Total Debt to Equity 105.1%
Interest Coverage 5
Management Effectiveness
Return On Assets 3.7%
Ret/ On Assets - 3 Yr. Avg. 6%
Return On Total Capital 3.5%
Ret/ On T. Cap. - 3 Yr. Avg. 6.3%
Return On Equity 7.4%
Return On Equity - 3 Yr. Avg. 12.3%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 42.2%
Gross Margin - 3 Yr. Avg. 42.5%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 21.5%
Operating Margin 12.2%
Oper. Margin - 3 Yr. Avg. 16.8%
Pre-Tax Margin 9.2%
Pre-Tax Margin - 3 Yr. Avg. 14%
Net Profit Margin 5.8%
Net Profit Margin - 3 Yr. Avg. 9.2%
Effective Tax Rate 36.6%
Eff/ Tax Rate - 3 Yr. Avg. 34.7%
Payout Ratio 18.9%

SRCL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SRCL stock intrinsic value calculation we used $3562 million for the last fiscal year's total revenue generated by Stericycle. The default revenue input number comes from 2016 income statement of Stericycle. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SRCL stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8.2%, whose default value for SRCL is calculated based on our internal credit rating of Stericycle, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Stericycle.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SRCL stock the variable cost ratio is equal to 83.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for SRCL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Stericycle.

Corporate tax rate of 27% is the nominal tax rate for Stericycle. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SRCL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SRCL are equal to 71.5%.

Life of production assets of 24.7 years is the average useful life of capital assets used in Stericycle operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SRCL is equal to 7.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2806 million for Stericycle - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 86.862 million for Stericycle is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Stericycle at the current share price and the inputted number of shares is $7.4 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
SMED Sharps Complia 4.47 0.94  str.sell
WM Waste Manageme 73.38 33.12  str.sell
CLH Clean Harbors 57.13 8.90  str.sell
ECOL US Ecology 46.35 18.31  str.sell

COMPANY NEWS

▶ ETFs with exposure to Stericycle, Inc. : April 17, 2017   [Apr-17-17 01:07PM  Capital Cube]
▶ Stericycle Setting Up for a Breakout   [Apr-13-17 03:17PM  TheStreet.com]
▶ Stericycle to Participate in Two Investor Events in May   [Apr-12-17 04:02PM  GlobeNewswire]
▶ ETFs with exposure to Stericycle, Inc. : April 5, 2017   [Apr-05-17 05:30PM  Capital Cube]
▶ 3 Profitable Healthcare Services Firms at Good Prices   [Mar-10-17 06:00AM  Morningstar]
▶ Goldman Sachs Relents: Stericycle Upgraded to Neutral   [Mar-07-17 12:33PM  Motley Fool]
▶ Stericycle Statement on Class Certification   [02:23PM  GlobeNewswire]
▶ The Hot Stock: Stericycle Jumps 7.7%   [Feb-16-17 04:36PM  at Barrons.com]
▶ Why Stericycle Stock Jumped 12% on Thursday   [01:05PM  at Motley Fool]
▶ 3 Stocks the Smartest Investors are Buying Right Now   [Dec-20-16 07:36AM  at Motley Fool]
▶ 10 Biggest Stock Market Flops of 2016   [Dec-16-16 10:10AM  at Kiplinger]
▶ Austin's biggest public company loses spot on Nasdaq-100 index   [Dec-14-16 09:35AM  at bizjournals.com]
▶ Changing Healthcare Landscape Benefits Stericycle   [Dec-12-16 07:00AM  at Morningstar]
▶ Here is What Hedge Funds Think About Stericycle Inc (SRCL)   [Nov-30-16 10:37AM  at Insider Monkey]
▶ 3 Takeaways From Stericycle's Q3 Earnings   [Nov-07-16 12:24PM  at Motley Fool]
▶ Stericycle to Present at NASDAQ Conference in November   [Nov-01-16 06:12PM  GlobeNewswire]
▶ Smart Money is Betting on These Environmental Services Stocks   [Sep-26-16 09:01AM  at Insider Monkey]
▶ 3 Value Stocks Near 52-Week Lows Worth Buying   [Sep-20-16 11:40AM  at Motley Fool]
▶ Ericsson, Verifone in Mondays 52-Week Low Club   [Sep-19-16 04:04PM  at 24/7 Wall St.]
▶ Stericycle, Cameco Among 5 Stocks That Hit 52-Week Lows This Week   [Sep-11-16 11:15AM  at Insider Monkey]
▶ 3 Warren Buffett Stocks to Buy in September   [09:39AM  at Motley Fool]
Stock chart of SRCL Financial statements of SRCL
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.